Treatment and prevention of neuropathology associated with neurodegenerative diseases
Administering a live, attenuated Bordetella pertussis -based vaccine to a subject at risk for developing a neurodegenerative disease featuring Aβ brain plaques can prevent or reduce the amount of Aβ brain plaques that would have developed in the subject without such treatment.
1. A method for preventing or reducing β-amyloid plaque in the brain of a subject having or at risk for developing Alzheimer's disease, the method comprising the step of administering to the subject a vaccine comprising a pharmaceutically suitable excipient or carrier and a sufficient number of live, attenuated Bordetella pertussis bacteria to colonize the subject and induce a protective response in the subject that reduces the amount of β-amyloid plaque that would have formed or would have been present in the brain of the subject if the subject were not administered the composition.
2. The method of claim 1 , wherein the vaccine is formulated for mucosal administration.
3. The method of claim 1 , wherein the vaccine is formulated for intranasal administration.
4. The method of claim 1 , wherein the vaccine is lyophilized and then reconstituted prior to administration.
5. The method of claim 1 , wherein the vaccine comprises approximately 5×10 8 , 1×10 9 , 5×10 9 , or 1×10 10 live, attenuated Bordetella pertussis bacteria.
6. The method of claim 1 , wherein the live attenuated Bordetella pertussis bacteria comprises a mutated pertussis toxin gene, a deleted or mutated dermonecrotic gene, and a heterologous ampG gene which replaces the Bordetella pertussis ampG gene.
7. The method of claim 6 , wherein the live attenuated Bordetella pertussis bacteria is a BPZE1 strain deposited with the Collection Nationale de Culture Microorganismes (C.N.C.M.) on Mar. 9, 2006, under accession number 1-3585.
8. The method of claim 1 , wherein the live attenuated Bordetella pertussis bacteria is non-virulent.
9. The method of claim 1 , wherein the subject has been diagnosed with Alzheimer's disease.
10. The method of claim 1 , wherein the subject has been diagnosed with mild cognitive impairment.
11. The method of claim 1 , wherein the subject has mutations in at least one of the genes consisting of the group of genes encoding amyloid precursor protein, presenilin I, and presenilin II.
12. The method of claim 1 , wherein the subject has an apolipoprotein E allotype that features one or two epsilon-4 alleles.
13. The method of claim 1 , wherein the subject has a subclinical Bordetella pertussis infection.